AUG 19, 2026 · PHASE 2 TRIAL
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
ClinicalTrials.gov
This is an active, ongoing Phase 2 trial registration with no results posted; the design and planned endpoints are reported but outcome data are not yet available.
Reported
Planned enrollment76
PhasePhase 2
Primary outcome measurePFS (Progression-Free Survival), assessed f…